rhosis, hepatic malignancy, or paracetamol overdose, or who were undergoing partial hepatectomy or liver transplantation, were assayed for t-PA, PAI-1, t-PA-PAI-1 complex and PAI-2 antigen values using specific enzyme linked immunosorbent assays (ELISAs) developed in this laboratory. Results-Appreciable increases in the plasma concentration of t-PA, PAI-1, and t-PA-PAI-i were seen in patients with alcoholic cirrhosis, primary biliary cirrhosis, and hepatic malignancy. Liver damage due to paracetamol overdose and partial hepatectomy both resulted in a striking increase in plasma PAI-i concentration, although concentrations of t-PA and t-PA-PAI-i complex were less affected. Concentrations of t-PA, PAI-1, and t-PA-PAI-i complex returned to near normal values after successful liver transplantation in a patient with chronic active hepatitis. PAI-2 was also detected in several patients with chronic liver disorders.
Conclusions-Haemorrhage due to fibrinolytic bleeding is commonly associated with liver disease. The patients studied here all had appreciable increases in circulating t-PA antigen concentrations. This was associated with increased concentrations of PAI-i antigen and t-PA-PAI-1 complex and the balance between activator and inhibitor did not result in systemic plasmin generation. Reduced PAM-1 activity in cirrhosis or a critical difference in the ratio of t-PA to PAI-1 concentrations may explain the enhanced plasminogen activator activity previously noted in cirrhosis but not metastatic disease. Reduced hepatic clearance of t-PA and t-PA-PAI-I complex due to impaired liver function may account for increased concentrations offree and complexed t-PA. ( In the three main groups of liver disorder studied-namely alcoholic cirrhosis, primary biliary cirrhosis, and hepatic malignancy-plasma concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex antigens were appreciably raised (table 2). t-PA and t-PA-PAI-1 complex antigen concentrations were highest in alcoholic cirrhosis, while PAI-1 antigen concentrations was highest in hepatic metastases. The concentration of PAI-1 in the platelet pool in each group was reduced; however, this reflected reduced platelet counts and the mean platelet content of PAI-1 did not differ from that of normal subjects (data not shown).
The two patients with severe chemical damage to the liver caused by paracetamol overdose showed strikingly raised concentrations of PAI-1 but only a modest increase in t-PA and t-PA-PAI-1 antigen (table 2) .
The changes in PAI-1, t-PA, and t-PA-PAI-I complex antigen induced by acute mechanical trauma to the liver (partial hepatectomy) were also studied (figure). A dramatic rise and rapid fall in PAI-1 antigen values was observed over 48 hours. Concentrations of t-PA and t-PA-PAI-1 complex rose also, but these rises followed rather than coincided with the PAI-I response.
In the patient with end stage liver failure, concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex before transplantation were all 15 000 r o 10 000 17 Our earlier studies have shown that despite raised concentrations of PA and reduced concentration of a2 antiplasmin there was no evidence of significant generation of plasmin-a2 antiplasmin complexes in patients with cirrhosis.89 This suggested that in cirrhosis there was sufficient inhibitor of PA present in plasma to prevent large scale generation of plasmin by the increased amounts of PA present. This study confirms this suggestion, as there is clearly a considerably increased concentration of PAI-1 in the plasma of cirrhotic patients, with generation of large quantities of t-PA-PAI-1 complex.
In the three major liver diseases studiedalcoholic cirrhosis, primary biliary cirrhosis, and metastatic liver disease-concentrations of t-PA, PAI-1 antigen, and t-PA-PAI-1 complexes were all considerably raised. Despite the raised concentration of PAI-1 antigen noted here, we observed reduced PA-I activity in hepatic cirrhosis4 18 and others have reported similar findings'7; this may reflect large scale generation of t-PA-PA-I complex in cirrhosis and explain why significant t-PA activity remains, accounting for enhanced overall fibrinolytic activity. The differences in overall fibrinolytic activity between patients with cirrhosis and those with metastatic liver disease may depend on a critical balance between t-PA and PAI-1. Concentrations of t-PA and PAI-I were raised in all patient groups, but clearly the ratio of t-PA to PAI-1 antigen concentrations was higher in cirrhosis than in metastatic disease (table 2) .
The highest concentrations of PAI-1 antigen were noted in patients with chemical (paracetamol) or physical (partial hepatic resection) injury to the liver. Paracetamol overdose represents a particularly acute form of liver damage and PAI-1 concentrations clearly were raised early, before large changes in standard biochemical variables of liver damage were detected; in this it is similar to the well known prolongation of the prothrombin time after overdose. Similar very early release of PAI-I antigen occurred during partial hepatectomy in the one patient studied and this occurred before any change in concentration of t-PA or t-PA-PAI-I complex.
These observations suggest that in liver disease the source of raised plasma concentrations of PAI-I is the liver itself, PAI-1 being released from damaged liver cells at least in some situations. The source of raised concentrations of t-PA is less clear. The liver is not rich in t-PA but is responsible for clearance of t-PA from the circulation both in its free and complexed forms.'9-21 In liver disease it seems probable that raised concentrations of t-PA and t-PA-PAI-i complexes result in part at least from reduced clearance mechanisms of both types. The restoration to virtual normality of t-PA, PAI-1, and tPA-PAI-I complexes after liver transplantation strikingly emphasises the central role of the liver in securing homoeostasis in the fibrinolytic system. PAI-2 is usually detected in pregnancy and has not been reported before in liver disease. This inhibitor is, however, synthesised by several cell lines in culture, including monocytes, macrophages, and certain tumour cells. In this study small but significant quantities of PAI-2 were detected by ELISA and by the independent technique of non-denaturing gel electrophoresis with zymography rendered specific by antibody quenching.22 The presence of PAI-2 may represent a response to the u-PA we have shown in the plasma in some forms of liver disease9 and which is often present in malignant cells. 23 Alternatively, depressed hepatic function may reduce clearance mechanisms for PAI-2, which are as yet undefined, and may result in small quantities of PAI-2 produced by monocytes, etc, accumulating in the plasma.
In summary, this study shows that patients with major hepatic disease tend to have high concentrations of t-PA, PAI-I, and t-PA-PAI-1 complex as detected by immunoassay, regardless of the type of liver disease. High concentrations of PAI-1 and perhaps PAI-2 may be an important factor in preventing generation of plasmin in these patients but do not account for the difference in overall fibrinolytic activity between patients with different forms of liver disease. Altered functional activity of the inhibitors or critical alterations of the ratio of t-PA to PA-1 concentration may be factors in the differences observed in PA activity. The raised concentrations of PAI-synthesis within or outwith the liver as a result of the metabolic disruption occurring in liver disease may occur. Raised t-PA concentrations may reflect, in part, reduced clearance by the damaged liver.
